PMID- 33660848
OWN - NLM
STAT- MEDLINE
DCOM- 20211103
LR  - 20211103
IS  - 1879-3479 (Electronic)
IS  - 0020-7292 (Linking)
VI  - 155
IP  - 3
DP  - 2021 Dec
TI  - Comparison of preoperative serum neopterin, periostin, indoleamine 
      2,3-dioxygenase, YKL-40, and tenascin-C levels with current tumor markers for 
      early-stage endometrial cancer.
PG  - 417-424
LID - 10.1002/ijgo.13666 [doi]
AB  - OBJECTIVE: To compare the predictive value of serum levels of neopterin, 
      periostin, YKL-40, tenascin-C (TNC), and indoleamine 2,3-dioxygenase (IDO) with 
      current tumor markers for the primary diagnosis of early-stage endometrial 
      cancer. METHODS: A prospective cross-sectional study was conducted between 
      January 2020 and November 2020. A total of 59 patients (38 women newly diagnosed 
      with early-stage endometrial cancer [study group] and 21 women with benign 
      endometrial pathologies [control group]) were enrolled. Blood samples were 
      collected prior to surgery and underwent immunoassay analysis. RESULTS: 
      Carcinoembryonic antigen (CEA), periostin, and IDO levels were significantly 
      higher in the study group than the control group (P = 0.008, P = 0.034, and 
      P = 0.003, respectively). Receiver operating characteristic curve analysis 
      revealed that IDO, periostin, and CEA were good predictors of early-stage 
      endometrial cancer (AUC = 0.733, 95% CI, 0.602-0.840, P < 0.002; AUC = 0.668, 95% 
      CI, 0.533-0.785, P = 0.018; and AUC = 0.709, 95% CI, 0.576-0.820, P = 0.002, 
      respectively). Correlation analysis revealed no significant correlation of any 
      biomarker with age or body mass index in either the control or study group. 
      CONCLUSION: Serum CEA, periostin, and IDO levels were significantly higher in 
      women with endometrial cancer than in those without cancer. These results may 
      help identify new markers for diagnosing endometrial cancer.
CI  - (c) 2021 International Federation of Gynecology and Obstetrics.
FAU - Unuvar, Songul
AU  - Unuvar S
AD  - Department of Pharmaceutical Toxicology, Faculty of Pharmacy, University of 
      Inonu, Malatya, Turkey.
FAU - Melekoglu, Rauf
AU  - Melekoglu R
AUID- ORCID: 0000-0001-7113-6691
AD  - Department of Obstetrics and Gynecology, Faculty of Medicine, University of 
      Inonu, Malatya, Turkey.
FAU - Turkmen, Nese B
AU  - Turkmen NB
AD  - Department of Pharmaceutical Toxicology, Faculty of Pharmacy, University of 
      Inonu, Malatya, Turkey.
FAU - Yilmaz, Ercan
AU  - Yilmaz E
AD  - Department of Obstetrics and Gynecology, Faculty of Medicine, University of 
      Inonu, Malatya, Turkey.
FAU - Yasar, Seyma
AU  - Yasar S
AD  - Department of Biostatistics and Medical Informatics, Faculty of Medicine, 
      University of Inonu, Malatya, Turkey.
FAU - Yuce, Hande
AU  - Yuce H
AD  - Department of Pharmaceutical Toxicology, Faculty of Pharmacy, University of 
      Inonu, Malatya, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20210324
PL  - United States
TA  - Int J Gynaecol Obstet
JT  - International journal of gynaecology and obstetrics: the official organ of the 
      International Federation of Gynaecology and Obstetrics
JID - 0210174
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Chitinase-3-Like Protein 1)
RN  - 0 (Indoleamine-Pyrrole 2,3,-Dioxygenase)
RN  - 0 (Tenascin)
RN  - 670-65-5 (Neopterin)
SB  - IM
MH  - Biomarkers, Tumor
MH  - Chitinase-3-Like Protein 1
MH  - Cross-Sectional Studies
MH  - *Endometrial Neoplasms/diagnosis
MH  - Female
MH  - Humans
MH  - *Indoleamine-Pyrrole 2,3,-Dioxygenase
MH  - Neopterin
MH  - Prospective Studies
MH  - Tenascin
OTO - NOTNLM
OT  - YKL-40
OT  - endometrial cancer
OT  - indoleamine 2,3-dioxygenase
OT  - neopterin
OT  - periostin
OT  - tenascin-C
OT  - tumor biomarkers
EDAT- 2021/03/05 06:00
MHDA- 2021/11/04 06:00
CRDT- 2021/03/04 08:40
PHST- 2021/02/16 00:00 [revised]
PHST- 2020/12/30 00:00 [received]
PHST- 2021/03/03 00:00 [accepted]
PHST- 2021/03/05 06:00 [pubmed]
PHST- 2021/11/04 06:00 [medline]
PHST- 2021/03/04 08:40 [entrez]
AID - 10.1002/ijgo.13666 [doi]
PST - ppublish
SO  - Int J Gynaecol Obstet. 2021 Dec;155(3):417-424. doi: 10.1002/ijgo.13666. Epub 
      2021 Mar 24.